Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Brownell

Foot and Ankle Surgery Philadelphia, PA Doctor of Podiatric Medicine

NPI 1366897431 CMS profile 4221328

3400 Civic Center Blvd Fl 4, Philadelphia, PA 19104

Open in the dashboard

General payments

$43,016

211 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Brownell of Philadelphia, PA is reported in the CMS Open Payments database as having received $43,016 across 211 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,220 65
2024 General $3,294 52
2023 General $589 29
2022 General $5,269 37
2021 General $2,553 24
2019 General $91 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Brownell
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to William Brownell were reported at $31,220. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year William Brownell Foot and Ankle Surgery median Middle half National median
2019 $91 $1,327 $279–$5,421 $163
2020 $0 $795 $121–$3,473 $114
2021 $2,553 $1,289 $201–$4,963 $132
2022 $5,269 $1,539 $270–$6,067 $149
2023 $589 $1,117 $257–$5,264 $160
2024 $3,294 $1,064 $235–$4,944 $164
2025 $31,220 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $30,629 103 payments
  2. Stryker Corporation $5,900 53 payments
  3. Arthrex, Inc. $3,240 15 payments
  4. Orthofix Medical, Inc. $1,760 18 payments
  5. Liberty Surgical, Inc $457 3 payments
  6. Integra LifeSciences Corporation $154 1 payment
  7. Sanara MedTech Inc. $150 1 payment
  8. Aroa Biosurgery Incorporated $144 3 payments
  9. Organogenesis Inc. $142 1 payment
  10. BioXcel Therapeutics, Inc. $122 1 payment
  11. Other $316 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,313 7 payments
  2. Food and Beverage $7,716 169 payments
  3. Travel and Lodging $7,587 33 payments
  4. Education $2,400 2 payments
Products named General payments · program years 2019–2025
  1. GRAFIX $26,139 11 payments
  2. STRAVIX Extremities & Limb Restoration $21,868 11 payments
  3. OASIS $17,427 24 payments
  4. GRAFIX PL $10,456 7 payments
  5. GRAFIX XC $10,000 3 payments
  6. NA Sports Med Knee $10,000 3 payments
  7. NA Sports Med Resection $4,500 1 payment
  8. PROSTEP $2,450 16 payments
  9. TrueLok $1,651 17 payments
  10. STRAVIX Extremities & Limb Restoration $1,425 27 payments
  11. Other $12,961 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

439

Median for Podiatry: 160

Drug cost

$35,630

Median for Podiatry: $2,368

Branded share of claims

12.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 19 $28,664
Ciclopirox Generic 107 $2,978
Mupirocin Generic 122 $1,024
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 17 $873
Ammonium Lactate Generic 38 $640
Diclofenac Sodium Generic 21 $483
Doxycycline Hyclate Generic 27 $299
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 17 $196
Ketoconazole Generic 14 $188
Meloxicam Generic 22 $106

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$152,556

Medicare's payments for the services billed

Medicare patients

213

Average age 69

Services billed

1,266

103 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 62%
Chronic kidney disease 52%
Heart failure 40%
Ischemic heart disease 40%
Depression 34%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IGALMI
  • BioXcel Therapeutics, Inc. $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record